VIDEO: Serum amyloid A could be IBD biomarker

HONOLULU – Serum amyloid A levels may offer an effective biomarker to gauge disease activity in inflammatory bowel disease, while baseline fecal calprotectin levels could help predict how patients with IBD will respond to anti-tumor necrosis factor therapy, according to two studies presented at the annual meeting of the American College of Gastroenterology.

“There’s a really high need for biomarkers in order to have a better assessment and better control of disease activity, before treatment and then throughout therapy,” explained the studies’ lead author, Dr. Andres Yarur of the University of Chicago.

In an interview at the meeting, Dr. Yarur discussed the two studies’ results, and how serum amyloid A levels, in combination with C-reactive protein levels, may improve clinicians’ ability to identify active endoscopic disease.

HONOLULU – Serum amyloid A levels may offer an effective biomarker to gauge disease activity in inflammatory bowel disease, while baseline fecal calprotectin levels could help predict how patients with IBD will respond to anti-tumor necrosis factor therapy, according to two studies presented at the annual meeting of the American College of Gastroenterology.

“There’s a really high need for biomarkers in order to have a better assessment and better control of disease activity, before treatment and then throughout therapy,” explained the studies’ lead author, Dr. Andres Yarur of the University of Chicago.

In an interview at the meeting, Dr. Yarur discussed the two studies’ results, and how serum amyloid A levels, in combination with C-reactive protein levels, may improve clinicians’ ability to identify active endoscopic disease.

HONOLULU – Serum amyloid A levels may offer an effective biomarker to gauge disease activity in inflammatory bowel disease, while baseline fecal calprotectin levels could help predict how patients with IBD will respond to anti-tumor necrosis factor therapy, according to two studies presented at the annual meeting of the American College of Gastroenterology.

“There’s a really high need for biomarkers in order to have a better assessment and better control of disease activity, before treatment and then throughout therapy,” explained the studies’ lead author, Dr. Andres Yarur of the University of Chicago.

In an interview at the meeting, Dr. Yarur discussed the two studies’ results, and how serum amyloid A levels, in combination with C-reactive protein levels, may improve clinicians’ ability to identify active endoscopic disease.